Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany

NCT03754803 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT03754803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03754803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
Lead sponsor
ViiV Healthcare
Phase
Observational
Overall status
Completed
Start date
November 8, 2018
Completion date
May 6, 2024
Enrollment
376 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections